Atrium Therapeutics, Inc. (RNA) has 20 tenedores institucionales e internos conocidos registrados. El mayor tenedor es RTW INVESTMENTS, LP con 4,795,000 acciones. Otros tenedores destacados incluyen Boyce Sarah y Edwards Martin.
En los últimos 12 meses, los internos han realizado 12 transacciones en RNA acciones — 8 compras (valoradas en $674.69K) y 2 ventas (valoradas en $685.24K). Las compras internas han superado las ventas durante este período, lo que puede señalar confianza en las perspectivas de la empresa.
RNA Participación de Insiders
Principal Titular
RTW INVESTMENTS, LP
4,795,000 acciones
Compras (12 meses)
8
$674.69K valor
Ventas (12 meses)
2
$685.24K valor
Actividad de Transacciones (12 meses)
Principales Titulares Internos
| # |
Nombre |
Cargo |
Acciones en Propiedad |
Última Declaración |
Tamaño Relativo |
| 1 |
Rtw Investments, Lp |
10 Percent Owner |
4,795,000 |
2021-08-06 |
|
| 2 |
Boyce Sarah |
President and CEO |
305,871 |
2025-03-21 |
|
| 3 |
Edwards Martin |
Director |
136,776 |
2021-01-04 |
|
| 4 |
Mccarthy Teresa |
Chief Human Resources Officer |
97,130 |
2025-03-21 |
|
| 5 |
Maclean Michael F |
Chief Financial Officer |
96,720 |
2025-03-21 |
|
| 6 |
Baroldi Joseph |
Chief Operating Officer |
87,000 |
2021-02-04 |
|
| 7 |
Kim Jae B. |
Chief Medical Officer |
82,000 |
2021-02-04 |
|
| 8 |
Flanagan W. Michael |
Chief Scientific Officer |
80,195 |
2025-06-12 |
|
| 9 |
Hughes Steven George |
Chief Medical Officer |
72,850 |
2025-03-21 |
|
| 10 |
Gallagher Kathleen P. |
Chief Program Officer |
50,392 |
2025-06-18 |
|
| 11 |
Mosbrooker Eric |
Chief Commercial Officer |
50,000 |
2025-01-08 |
|
| 12 |
Moriarty John B |
Chief Legal Officer |
50,000 |
2025-01-08 |
|
| 13 |
Calderaro Charles Iii |
Chief Technical Officer |
40,000 |
2025-01-08 |
|
| 14 |
Wong Roderick |
10 Percent Owner |
15,000 |
2021-06-17 |
|
| 15 |
Levin Arthur A |
Director |
10,034 |
2025-06-12 |
|
| 16 |
Wilson Troy Edward |
Director |
10,034 |
2025-06-12 |
|
| 17 |
Boess Carsten |
Director |
6,692 |
2025-06-12 |
|
| 18 |
Kaye Edward M. Md |
Director |
6,692 |
2025-06-12 |
|
| 19 |
Kim Jean Jinsun |
Director |
6,692 |
2025-06-12 |
|
| 20 |
Thompson Tamar |
Director |
6,692 |
2025-06-12 |
|
Transacciones Recientes (últimos 12 meses)
| Fecha |
Nombre |
Cargo |
Tipo |
Acciones |
Precio |
Valor |
| 2025-06-17 |
Gallagher Kathleen P. |
Chief Program Officer |
Venta Informativa |
911 |
$30.24 |
$27.55K |
| 2025-06-10 |
Skerjanec Simona |
Director |
Concesión de RSU |
6,692 |
- |
- |
| 2025-06-11 |
Flanagan W. Michael |
Chief Scientific Officer |
Venta Informativa |
20,000 |
$32.88 |
$657.69K |
| 2025-06-10 |
Kim Jean Jinsun |
Director |
Concesión de RSU |
6,692 |
- |
- |
| 2025-06-10 |
Thompson Tamar |
Director |
Concesión de RSU |
6,692 |
- |
- |
| 2025-06-10 |
Henig Noreen |
Director |
Concesión de RSU |
6,692 |
- |
- |
| 2025-06-10 |
Wilson Troy Edward |
Director |
Concesión de RSU |
10,034 |
$33.62 |
$337.34K |
| 2025-06-10 |
Kaye Edward M. Md |
Director |
Concesión de RSU |
6,692 |
- |
- |
| 2025-06-10 |
Boess Carsten |
Director |
Concesión de RSU |
6,692 |
- |
- |
| 2025-06-10 |
Levin Arthur A |
Director |
Concesión de RSU |
10,034 |
$33.62 |
$337.34K |
| 2025-06-02 |
Gallagher Kathleen P. |
Chief Program Officer |
Ejercicio de Opciones (Venta) |
5,875 |
$16.65 |
$97.82K |
| 2025-05-01 |
Gallagher Kathleen P. |
Chief Program Officer |
Ejercicio de Opciones (Venta) |
5,875 |
$16.65 |
$97.82K |
